Showing 4781-4790 of 9773 results for "".
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://practicaldermatology.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://practicaldermatology.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- Amlitelimab Shows Efficacy Across Phase 3 AD Trialshttps://practicaldermatology.com/news/amlitelimab-shows-efficacy-across-phase-3-ad-trials/2486422/Late-breaking Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting demonstrated that amlitelimab, a nondepleting anti–OX40 ligand (OX40L) antibody, significantly improved disease severity and symptoms in patients with moderate-to-severe atopic dermatitis (AD), b
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://practicaldermatology.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://practicaldermatology.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.